Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences, Inc. (RNA) Free Cash Flow (2019 - 2025)

Avidity Biosciences' Free Cash Flow history spans 7 years, with the latest figure at -$179.3 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 74.72% year-over-year to -$179.3 million; the TTM value through Dec 2025 reached -$663.8 million, down 118.13%, while the annual FY2025 figure was -$663.8 million, 118.13% down from the prior year.
  • Free Cash Flow reached -$179.3 million in Q4 2025 per RNA's latest filing, down from -$157.6 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $12.5 million in Q4 2023 to a low of -$198.3 million in Q2 2025.
  • Average Free Cash Flow over 5 years is -$66.3 million, with a median of -$44.0 million recorded in 2022.
  • Peak YoY movement for Free Cash Flow: skyrocketed 133.41% in 2023, then crashed 920.4% in 2024.
  • A 5-year view of Free Cash Flow shows it stood at -$29.8 million in 2021, then dropped by 25.58% to -$37.4 million in 2022, then surged by 133.41% to $12.5 million in 2023, then plummeted by 920.4% to -$102.6 million in 2024, then tumbled by 74.72% to -$179.3 million in 2025.
  • Per Business Quant, the three most recent readings for RNA's Free Cash Flow are -$179.3 million (Q4 2025), -$157.6 million (Q3 2025), and -$198.3 million (Q2 2025).